Chordate Medical Holding AB (publ)

As of June 30, 2025, Chordate Medical Holding AB (publ) has 2.70M shares outstanding.

These figures are as of June 30, 2025. The price-to-sales ratio is 12.17, and the price-to-book ratio stands at 0.70.

These figures are as of June 30, 2025. The EV/Sales ratio of 7.90 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative.

As of June 30, 2025, Chordate Medical Holding AB (publ) maintains a current ratio of 1.97, meaning it holds 2.0x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2025, Chordate Medical Holding AB (publ) posted a negative return on equity (ROE) of -186.89, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -112.58, reflecting losses generated across the asset base. Inventory turnover of 0.10 indicates how many times Chordate Medical Holding AB (publ) sells and replaces its inventory over a year, a key working capital efficiency ratio.

As of the close on March 4, 2026, Chordate Medical Holding AB (publ)'s stock has declined approximately 98.97% over the past 52 weeks. The 50-day moving average sits at 0.65, while the 200-day moving average is 4.21.

Over the twelve months ended June 30, 2025, Chordate Medical Holding AB (publ) posted a gross margin of 81.34, reflecting its pricing power and cost economics. The operating margin of -2,538.32 and net profit margin of -2,532.89 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2025. Free cash flow yield is negative at -195.30: the business is consuming cash rather than generating it, so any dividend is not covered by free cash flow. Total shareholder yield is negative at -152.33, meaning Chordate Medical Holding AB (publ) raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Chordate Medical Holding AB (publ)'s most recent stock split took place on August 29, 2024 with a 500:1 split ratio.

As of June 30, 2025, Chordate Medical Holding AB (publ) has an Altman Z-Score of -5.54, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.